Friday, July 10, 2026

Drug profile · INN

eravacycline

eravacycline (XERAVA) is a bacterial 70s ribosome inhibitor.

EMA: approved Antiinfectives for systemic use (J01) J01AA13
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — eravacycline
Class
Antiinfectives for systemic use (J01)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

eravacycline (XERAVA) is a bacterial 70s ribosome inhibitor.

Key facts

INN eravacycline
Brand XERAVA
Mechanism Bacterial 70S ribosome inhibitor
Target Bacterial 70S ribosome
Therapeutic class Antiinfectives for systemic use (J01)
ATC code J01AA13

Mechanism of action

Bacterial 70S ribosome inhibitor

Primary target: Bacterial 70S ribosome

Approval history

Authority Status Date
EMA approved

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. azithromycin Bacterial 70S ribosome inhibitor
  3. chloramphenicol Bacterial 70S ribosome inhibitor
  4. clarithromycin Bacterial 70S ribosome inhibitor
  5. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor

Frequently asked questions

What is eravacycline?

eravacycline (XERAVA) is a bacterial 70s ribosome inhibitor.

What is the brand name for eravacycline?

XERAVA is a marketed brand name for eravacycline. Check FDA Drugs@FDA for the current US label holder and prescribing information.